No Data
No Data
Magic Pharmaceutical (600613.SH) announced first-quarter results, net profit of 239.447 million yuan, an increase of 0.65%
According to Zhitong Finance App News, Magic Pharmaceutical (600613.SH) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 575 million yuan, a year-on-year decrease of 1.42%. Net profit attributable to shareholders of listed companies was 239.447 million yuan, an increase of 0.65% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 237.719 million yuan, an increase of 1.11% over the previous year.
Magic Pharmaceutical (600613.SH) announced its 2023 annual results, with net profit of 57.007 million yuan, an increase of 17.41% year-on-year
Magic Pharmaceutical (600613.SH) released its 2023 annual performance report. The company achieved operating income of 2 during the reporting period...
The controlling shareholder of Magic Pharmaceutical (600613.SH) plans to transfer 5.62% of its shares to Zhiji 2 at a price of 192 million yuan
Magic Pharmaceutical (600613.SH) announced that the controlling shareholder of the company, Guizhou Magic Holdings (Group) Co., Ltd. (abbreviation...
Magic Pharmaceutical (600613.SH): Subsidiary company obtained high-tech enterprise certificate
Gelonghui, Feb. 22 | Magic Pharmaceutical (600613.SH) announced that its holding subsidiaries, Guizhou Magic Pharmaceutical Co., Ltd., Guizhou Bai Compulsory Pharmaceutical Co., Ltd., and its subsidiary company Guizhou Junzhitang Pharmaceutical Co., Ltd. recently received the “High-tech Enterprise Certificate” jointly issued by the Guizhou Provincial Department of Science and Technology, the Guizhou Provincial Department of Finance, and the Guizhou Provincial Taxation Bureau of the State Administration of Taxation.
[BT Financial Report Momentary Analysis] Fantastic Pharmaceuticals 2023 Quarterly Report: Financial Performance and Market Challenges Under Steady Operation
Magic Pharmaceutical (stock code: 600613), as a leader in the proprietary Chinese medicine and chemical drug segment in the pharmaceutical manufacturing industry, the financial report for the third quarter of 2023 revealed the company's operating conditions in the context of a slowdown in the overall growth rate of the industry. In the face of the cost pressure brought about by the continued rise in the price of Chinese herbal medicines, Wonder Pharmaceuticals has maintained a relatively steady financial performance. In terms of assets and liabilities, the total assets of Wonder Pharmaceuticals decreased from 3.381 billion yuan at the end of the previous year to 3.212 billion yuan, showing a slight reduction. Total liabilities fell from $1,008 billion at the end of the previous year to $821 million, a decrease of approximately 18.6 billion
Miracle Pharmaceutical (600613.SH) released the first three quarter results, net profit of 65.95 million yuan, an increase of 18.94% over the previous year
Miracle Pharmaceutical (600613.SH) disclosed its report for the third quarter of 2023. The company achieved revenue of 17 in the first three quarters...
No Data